ArticleThe New England journal of medicine2014
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Efficacy and Safety of Bilateral Deep Brain Stimulation (DBS) for Severe Alzheimer's Disease: A Comparative Analysis of Fornix Versus Basal Ganglia of Meynert.CNS neuroscience & therapeutics · 2025Observational
- Exploring the Synergistic Effects of Erinacines on Microglial Regulation and Alzheimer's Pathology Under Metabolic Stress.CNS neuroscience & therapeutics · 2024Article
- Deep brain stimulation of the nucleus basalis of Meynert in severe Alzheimer's disease.Journal of Alzheimer's disease reports · 2024Article
- Deep brain stimulation versus nonsurgical treatment for severe Alzheimer's disease: A long-term retrospective cohort study.Journal of Alzheimer's disease reports · 2024Article
- Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges.Aging and disease · 2022Article
- Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease.International journal of molecular sciences · 2022Review
- Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies.International journal of molecular sciences · 2021Article
- Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features.Scientific reports · 2020Article
- Advances in developing novel therapeutic strategies for Alzheimer's disease.Molecular neurodegeneration · 2018Review
- Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease.GeroScience · 2017Article
- The Proteasome and Oxidative Stress in Alzheimer's Disease.Antioxidants & redox signaling · 2016Review
- Anti-dementia medications: current prescriptions in clinical practice and new agents in progress.Therapeutic advances in drug safety · 2015Review
- Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.CNS drugs · 2015Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24716688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.